Skip to main content
. 2019 Oct 30;3(21):3241–3247. doi: 10.1182/bloodadvances.2019000811

Table 1.

Baseline characteristics

Characteristic Participant
1 2 3
Age, y 43 50 47
Weight, kg 89 81 82
HIV status Negative Positive, controlled Positive, controlled
Hep B/Hep C Hep B negative Hep B negative Hep B negative
Hep C; resolved Hep C; resolved Hep C; resolved
Hemophilia B status FIX = 1% FIX <1% FIX <1%
Prescreening FIX regimen Prophylaxis (EHL FIX) Prophylaxis (EHL FIX) Prophylaxis (EHL FIX)
Annualized bleed rate 1 y before screening* 3 1 5
NAb titer (AAV5) (luciferase assay) Positive Positive Positive
48 44 25

EHL, extended half-life; Hep, hepatitis.

*

Total bleeds (treated + untreated).

AAV5 NAb is considered positive if titer is ≥2.15